Spotlight

All

Insights

Conversations

Progress

Press

Latest Posts

Progress CEO 2025 Year in Review

CEO Punit Dhillon discusses Skye's accomplishments in 2025 and execution plans for 2026.

Progress Third Quarter 2025 Financials & Operational Update Released November 12, 2025

Insights ObesityWeek Presentation: Additional P2a Study Data Released November 7, 2025

Insights

ObesityWeek Presentation: Additional P2a Study Data

Obesity specialist Louis Aronne, MD, highlights CB1 inhibitor weight loss, weight rebound (after therapy discontinuation) and waist circumference in new data from Skye’s CBeyond trial.

Released November 7, 2025

CBeyond P2a Data: Nimacimab as Mono and Combination Therapy

Phase 2a topline data highlights nimacimab as monotherapy and a combo with a GLP-1 therapeutic, semaglutide, with weight loss, tolerability and safety outcomes.

Released October 6, 2025

Nimacimab P1b Safety and Tolerability Data

Skye presents a summary of safety, tolerability, and pharmacokinetic data from the Phase 1b of nimacimab at diabetes/obesity conference.

Released September 19, 2025

Review: Preclinical Data and Unmet Needs for Obesity Therapeutics

Skye’s CEO and CMO get perspectives from three obesity specialists regarding new preclinical results and imminent CBeyond Phase 2a clinical trial data.

Released September 5, 2025

Reviewing Component Mechanisms of Peripheral CB1 Inhibitor Antibody

Skye’s CMO and CSO discuss key differentiating mechanistic components of its peripherally-restricted CB1-inhibiting antibody, nimacimab.

Released September 4, 2025

Comparing Weight Loss/Rebound between Distinct CB1 Inhibitors

Preclinical data assesses weight loss and rebound of peripheral CB1-inhibiting antibody, nimacimab, versus small molecule CB1 inhibitor, monlunabant.

Released September 4, 2025

Assessing Additive Effects when Combined with Tirzepatide

Data highlighting combination of nimacimab and suboptimal tirzepatide versus either drug alone in terms of weight loss, rebound and maintenance.

Released September 4, 2025

Assessing Nimacimab + Incretin Combination Weight Loss Dynamics

This research showed that nimacimab-driven weight loss is not a result of caloric deficit alone (via pair-fed study), as well as incremental weight rebound and maintenance benefits.

Released September 4, 2025

A Look at Manufacturing Nimacimab

Skye's COO discusses FDA requirements and considerations around manufacturing a monoclonal antibody such as nimacimab.

Released September 1, 2025

Conversations

Proven, Complementary Weight Loss Mechanism: CB1 Inhibition

The CB1 inhibition mechanism has shown clinically validated and meaningful weight loss. Nimacimab offers a differentiated, peripherally targeted approach with unique potential to complement GLP1/incretin therapeutics.

Released July 9, 2025

Heterogeneous Needs Not Fulfilled by Approved Incretin Drugs Alone

Tu Diep, Skye Bioscience's COO, discusses historical views toward obesity, its emerging acceptance as a disease, and unmet treatment needs left by GLP1/incretins.

Released July 6, 2025

The Bio Report Podcast: Obesity Therapy Unmet Needs

This podcast discusses unmet needs in the obesity space related to lack of tolerability, muscle loss, and weight rebound after therapy discontinuation, and the potential role of peripheral CB1 inhibition to help address these issues.

Released July 2, 2025

Skye + Obesity Specialists Discuss Non-incretin Therapeutics

Led by Evercore equity analysts, Skye executives join notable obesity physicians to discuss the CB1 pathway, Skye's peripheral CB1 inhibitor, and the broader non-incretin toolkit supporting obesity care beyond the limits of GLP-1s.

Released June 21, 2025

Chief Operating Officer: An Outlook on Work & Life

Tu Diep, Skye Bioscience's COO, discusses value and his perspective on making a positive contribution.

Released April 5, 2025

Expert Panel with Skye CEO + Obesity Specialist

South by Southwest panel with CEO Punit Dhillon and Clinical Advisor Beverly Tchang, MD, discusses need for sustainable weight loss, emerging advancements, combination therapies, and possibilities for CB1 inhibition.

Released March 10, 2025

SXSW 2025 Pre-panel Chat Covers Broad Obesity-related Topics

Skye CEO Punit Dhillon and Clinical Advisory Board Member Dr. Beverly Tchang, MD, chat about SXSW 2025 and weight loss ahead of their panel, “Weighing in on Weight Loss.”

Released March 9, 2025

COO Reflects on the Challenges and Path of His Journey

Tu Diep, Skye Bioscience's COO, discusses his lifelong passion, interest and work leading into the drug development journey of lead asset nimacimab.

Released March 5, 2025

Business of Biotech Podcast: Potential for Antibody CB1 Inhibitor

A discussion of the merits of an antibody-based CB1 inhibitor, potential lack of neuropsychiatric side effects, and potential role of a CB1 inhibitor in the realm of weigh loss therapeutics.

Released October 20, 2024

Progress

CEO 2025 Year in Review

CEO Punit Dhillon discusses Skye's accomplishments in 2025 and execution plans for 2026.

Released December 23, 2025

Third Quarter 2025 Financials & Operational Update

See Skye's Q3 2025 webcast, transcript and news release.

Released November 12, 2025

2025 Stockholder Letter

Skye's 2025 stockholder letter, part of its proxy package, reviews progress, why CB1 matters, and outlook.

Released April 29, 2025

CEO 2024 Year in Review

CEO Punit Dhillon discusses Skye’s accomplishments in 2024 and execution plans for 2025.

Released January 13, 2025

Press

Diet, Not Lack of Exercise, Is Driving Obesity

NPR: Evidence suggests dietary changes, more than reduced physical activity, are the primary factor in rising obesity rates. Exploring how what people eat may matter more than how much they move.

Released July 23, 2025

Driving New Approaches in Obesity Drug Development

xtalks: Skye Bioscience is pioneering a new approach to obesity drug development, focusing on peripheral CB1 inhibition to improve metabolic health.

Released April 24, 2025

Transformative Weight Loss Drugs not Without Risks

Men's Health: A new class of weight loss drugs are reshaping obesity treatment while also raising important questions about safety, side effects, and long-term use.

Released March 28, 2025

New Weight Loss Drugs Aim to Save Muscle

Reuters: A number of experimental obesity drugs are being developed to reduce fat while preserving muscle–key to long term health. Companies are racing to prove they can show functional benefits beyond weight loss.

Released February 19, 2025

The Health Risks and Benefits of Weight-Loss Drugs

TIME: New data on GLP-1 weight loss drugs like Wegovy and Ozempic highlight benefits for heart and brain health while noting risks such as gastrointestinal issues and other complications.

Released January 21, 2025

How Can You Tell if Your Weight Is a Problem

The Guardian: The Lancet Commission argues that BMI alone is misleading and proposes a shift toward assessing health impacts like organ function, fat distribution, and risk markers to decide when weight becomes a medical concern.

Released January 18, 2025

Advancing Nimacimab In The Anti-Obesity Market

in vivo: The advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics.

Released September 30, 2024